Navigation Links
Huifeng Bio-Pharmaceutical (HFGB) Provides Update on COS Application Status
Date:7/29/2008

COS Consultants Evaluate Purification Testing, Standards and Procedures

SHAANXI, China, July 29 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio- Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB), a leading developer and producer of plant extracts and raw materials used in the production of pharmaceuticals, nutraceuticals and food production, today released an investor update on the status of its application for COS approval for the delivery of Diosmin to Safic-Alcan.

COS, or European Certification of Suitability, approval is required before Huifeng can begin shipments of Diosmin to the European Community. As previously announced, Huifeng estimates COS approval in September.

In order to assure compliance with the application process, Huifeng recently retained and was visited by a certified COS approval consulting firm. The consultants performed a thorough, on-site inspection of Huifeng's Diosmin production facilities, including an evaluation of the purification testing, procedures and standards. In addition, the consultants provided the company with guidance pertaining to the COS application filing process.

"Huifeng is taking all necessary steps to keep pace with the established timeline for the COS application filing and approval process," stated Jing'An Wang, CEO/President of Huifeng. "Our COS consultants have not only assisted us in this process, but gave us very high marks regarding our Diosmin preparation and compliance with the COS standards."

COS certification is the final stage of approval for Huifeng to begin shipments of Diosmin to French company Safic-Alcan under a supply agreement announced last November. The supply agreement between Huifeng and Safic-Alcan grants Safic-Alcan exclusive rights to market Diosmin in the European market. The agreement also sets forth minimum guaranteed quantities to be delivered over each of the five years of the contract. The minimum quantity of Diosmin to be delivered in year one is 50 tons, increasing yearly to at least 500 tons in the last year of the contract.

Huifeng has been increasing their inventory of Diosmin in anticipation of COS approval and expects to be able to begin shipments to Safic-Alcan in the fall.

About Diosmin

Diosmin is a flavonoid that can be isolated from various plant sources or derived from the flavonoid hesperidin. Diosmin is used as a pharmaceutical material as a supplement to treat chronic venous insufficiency, hemorrhoids, lymphedema, and varicose veins.

About Huifeng Bio-Pharmaceutical Technology, Inc.

Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi'an, People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. More information can be found on the company's web site at: http://www.hfgb.cn/

Forward-Looking Statement Notice:

This press release includes "forward-looking statements" as defined by the Securities and Exchange Commission (the "SEC"), including statements regarding COS certification and shipments of products. All statements, other than statements of historical fact, included in the press release that address activities, events or developments that the company believes or anticipates will or may occur in the future are forward- looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors the company believes are appropriate under the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the company and may not materialize, including the timeline for COS approval, receipt of COS approval, delays in manufacturing or transporting product. Investors are cautioned that any such statements are not guarantees of future performance.

For more information, please contact:

Huifeng Bio-Pharmaceutical Technology, Inc.

Daniel Carlson, Primary Capital LLC.

Tel: +1-415-460-1165

Email: DCarlson@PrimaryLLC.com


'/>"/>
SOURCE Huifeng Bio-Pharmaceutical Technology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Huifeng Bio-Pharmaceutical (HFGB) Announces 2007 Full Year Results
2. Huifeng Bio-Pharmaceutical (HFGB) to Release First Quarter 2008 Earnings Results on May 15, 2008
3. Huifeng Bio-Pharmaceutical (HFGB) Announces No Earthquake Related Damage to Facilities
4. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on Current Business and COS Certification
5. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
6. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Skystar Bio-Pharmaceutical Raises 2007 Revenue Guidance to $15.8 Million
9. Leading Overseas Scientists Establish High-Tech Bio-Pharmaceutical Enterprise in Changzhou
10. Sentry Enhances Offerings with Temperature-Controlled Custom Bio-Pharmaceutical Finishing Services
11. CardioDynamics Provides 2007 Shareholder Meeting Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... 09, 2016 , ... There’s a winning streak at Voxx Analytics: the tech ... after winning the award last year as well. Employees nominate their companies for the ... Vesely pointed to the tech company’s upbeat environment as a reason. “We don’t answer ...
(Date:12/9/2016)... ... 09, 2016 , ... Aditya Humad, Acting CFO of AxioMed and Managing Partner ... United States, Axiomed is now gaining interest from Silicon Valley. “It was satisfying to ... went on to say that, “We expect interest to continue to rise as AxioMed ...
(Date:12/9/2016)... PHILADELPHIA , Dec. 9, 2016  A ... Temple University are moving one step closer to ... orthopedic applications. OrthoMend Research, Inc., a start-up company ... acquired the exclusive license for these novel absorbable ... to develop them for commercial use. The company ...
(Date:12/9/2016)... - Portage Biotech Inc. ("Portage" or "the Company") (OTC: ... that Biohaven has issued today the following press release: ... (PRWEB) Dec 9, 2016 - Biohaven Pharmaceutical Holding Company ... U.S. Food and Drug Administration ("FDA") has granted the ... BHV-0223, an orally dissolving tablet being developed for the ...
Breaking Biology Technology:
(Date:12/6/2016)... Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") today ... principal amount of its 1.414% senior unsecured notes due 2022 ... notes due 2026. The closing of the ... the satisfaction of customary closing conditions.  The notes will pay ... The Company intends to use the net proceeds from the ...
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe ... announced BioLock , an electrocardiogram (ECG) biosensor ... monitoring, a key IoT asset. The smart system ... a vehicle,s steering wheel and mobile devices to ... touch. As vehicle technology advances, so ...
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s ... ... DERMALOG is Germany's largest Multi-Biometric ... Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System is ...
Breaking Biology News(10 mins):